Investigator Initiated Trial: Diabetes and Obsesity
Lilly Diabetes & Obesity is committed to address the diverse needs of people with diabetes and obesity and consistently support patients as their needs change. We are focused on delivering solutions that will bring simplicity and ease of use in diabetes and obesity treatment and information on the effective, safe, timely, and appropriate use of a broad range of therapy in order to improve patient outcomes.
NOTE: Please be aware that only research requests coming from countries where tirzepatide has been approved for marketing for at least one indication and is commercially available will be considered for IIT support.
Overall considerations:
- Adequately designed small proof of concept studies will be prioritized
- Studies with treatment durations of 12 months or less will be prioritized
- Studies not requiring placebo-matched control or blinded tirzepatide will be prioritized
Areas of tirzepatide external research in scope:
- Concepts assessing whether reducing body weight and/or improving glucose control through tirzepatide therapy could provide clinical benefit
- Mechanism of action studies aiming to better understand the effects of tirzepatide
Documents
Tirzepatide external research out of scope:
- Studies in disease areas, patient populations or with study outcomes that are overlapping with any other study conducted or supported by Eli Lilly
- Oncology studies
- Studies similar in nature to proposals previously reviewed and declined by Lilly
- Non-clinical or pre-clinical research
- Studies involving dulaglutide
- Studies involving unapproved products or procedures
- Studies including pediatric populations
- Studies submitted by investigators associated with for-profit entities
PIRA™ suggested Proposal
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.